Get 20% lifetime commission for referring investors to digrin.com here.

Regulus Therapeutics Inc. (RGLS) Financials

Stock symbol RGLS is outdated, potentially delisted? Maybe it is available on other exchange?

RGLS Assets vs Liabilities

Date	Assets	Liabilities
Sept. 30, 2023	37.7 million	9.5 million
June 30, 2023	43.6 million	9.7 million
March 31, 2023	37.0 million	10.4 million
Dec. 31, 2022	46.7 million	13.4 million

RGLS Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.

Date	Free Cash Flow	Stock based compensation
Sept. 30, 2023	-6.8 million	973000
June 30, 2023	-6.3 million	382000
March 31, 2023	-8.1 million	410000
Dec. 31, 2022	-6.3 million	397000

RGLS Net Income

No data available :(

RGLS Cash and Debt

Graph available only for paid members. Upgrade to see it.

Date	Cash	Debt	Capital Lease
Sept. 30, 2023	30.8 million	-	1.2 million
June 30, 2023	37.3 million	-	1.4 million
March 31, 2023	30.3 million	-	1.6 million
Dec. 31, 2022	39.2 million	-	1.8 million

RGLS Shares Outstanding

Graph available only for paid members. Upgrade to see it.

Date	Shares Outstanding
Sept. 30, 2023	19.6 million
June 30, 2023	19.1 million
March 31, 2023	16.8 million
Dec. 31, 2022	16.8 million

RGLS Expenses

Graph available only for paid members. Upgrade to see it.

Date	Capex	R&D	G&A	S&M
Sept. 30, 2023	541000	5.5 million	2.6 million	-
June 30, 2023	-	5.0 million	2.3 million	-
March 31, 2023	1000	4.9 million	2.4 million	-
Dec. 31, 2022	63000	4.7 million	2.2 million	-

RGLS Cost of Revenue

Graph available only for paid members. Upgrade to see it.

Date	Revenue	Cost of Revenue
Sept. 30, 2023	-	56000
June 30, 2023	-	47000
March 31, 2023	-	48000
Dec. 31, 2022	-	33000

RGLS

Price: $8.16

52 week price:

0.83

8.35

Earnings Per Share: -0.68 USD

P/E Ratio: -12

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 68300

Ebitda: -14.7 million

Market Capitalization: 565.0 million

Links:

RGLS on Yahoo Finance